PDF(Pubmed)
Abstract：
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with prediabetes and type 2 diabetes mellitus (T2DM). Carnosine has been suggested as a potential approach to reduce ASCVD risk factors. However, there is a paucity of human data. Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM. In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo. We evaluated endothelial dysfunction, arterial stiffness, lipid parameters, blood pressure, heart rate, hepatic and renal outcomes before and after the intervention. Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure, endothelial function (logarithm of reactive hyperemia (LnRHI)), arterial stiffness (carotid femoral pulse wave velocity (CF PWV)), lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo. In conclusion, carnosine supplementation did not improve cardiovascular and cardiometabolic risk factors in adults with prediabetes and T2DM with good glycemic control. Therefore, it is improbable that carnosine supplementation would be a viable approach to mitigating the ASCVD risk in these populations. The trial was registered at clinicaltrials.gov (NCT02917928).
摘要：
动脉粥样硬化性心血管疾病（ASCVD）是糖尿病前期和2型糖尿病（T2DM）患者发病和死亡的主要原因。肌肽已被认为是减少ASCVD危险因素的潜在方法。然而,人类数据很少。因此，我们进行了一项为期14周的双盲随机安慰剂对照试验,以确定肌肽与安慰剂相比是否能改善糖尿病前期和2型糖尿病患者的血管和代谢结局.总的来说,49名血糖控制良好的糖尿病前期和T2DM患者被随机分配接受2g/天肌肽或匹配的安慰剂。我们评估了内皮功能障碍，动脉僵硬度,脂质参数，血压,心率,干预前后的肝肾结局。肌肽补充对心率没有影响，外周和中枢血压，内皮功能（反应性充血对数（LnRHI）），动脉僵硬度（颈动脉股动脉脉搏波速度（CFPWV）），脂质参数，肝纤维化指标，肝脏瞬时弹性成像，肝功能检查,与安慰剂相比，肾脏结局。总之,对于血糖控制良好的糖尿病前期和2型糖尿病患者,补充肌肽不能改善心血管和心脏代谢危险因素.因此,在这些人群中,补充肌肽不可能成为降低ASCVD风险的可行方法.该试验在clinicaltrials.gov（NCT02917928）注册。
